Cartesian Therapeutics (RNAC) Profit After Tax: 2015-2025
Historic Profit After Tax for Cartesian Therapeutics (RNAC) over the last 11 years, with Sep 2025 value amounting to -$35.9 million.
- Cartesian Therapeutics' Profit After Tax fell 48.46% to -$35.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.0 million, marking a year-over-year increase of 80.40%. This contributed to the annual value of -$77.4 million for FY2024, which is 64.76% up from last year.
- According to the latest figures from Q3 2025, Cartesian Therapeutics' Profit After Tax is -$35.9 million, which was down 326.00% from $15.9 million recorded in Q2 2025.
- Over the past 5 years, Cartesian Therapeutics' Profit After Tax peaked at $28.8 million during Q1 2022, and registered a low of -$177.7 million during Q4 2023.
- Over the past 3 years, Cartesian Therapeutics' median Profit After Tax value was -$17.7 million (recorded in 2025), while the average stood at -$30.4 million.
- In the last 5 years, Cartesian Therapeutics' Profit After Tax tumbled by 3,114.73% in 2023 and then skyrocketed by 221.51% in 2024.
- Quarterly analysis of 5 years shows Cartesian Therapeutics' Profit After Tax stood at $12.2 million in 2021, then plummeted by 51.85% to $5.9 million in 2022, then tumbled by 3,114.73% to -$177.7 million in 2023, then soared by 94.23% to -$10.3 million in 2024, then crashed by 48.46% to -$35.9 million in 2025.
- Its Profit After Tax was -$35.9 million in Q3 2025, compared to $15.9 million in Q2 2025 and -$17.7 million in Q1 2025.